Treatment of hypertension in diabetes: a contemporary approach with a focus on improving cardiovascular outcomes

References

• Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta (GA): U.S. Department of Health and Human Services; 2014.
   Google Scholar
• American Diabetes Association. Chapter 8. Cardiovascular disease and risk management. Diabetes Care. 2015;38:S49–S57.
   PubMedGoogle Scholar
• Karuparthi PR, Yerram P, Lastra G, et al. Understanding essential hypertension from the perspective of the cardiometabolic syndrome. J Am Soc Hypertens. 2007;1(2):120–134.
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity among adults: United States, 2011–2012. NCHS data brief, no 131. Hyattsville (MD): National Center for Health Statistics; 2013.
   Google Scholar
• Kurukulasuriya LR, Stas S, Lastra G, et al. Hypertension in obesity. Med Clin North Am. 2011;95:903–917.
   PubMed Web of Science ®Google Scholar
• Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypetension. Ann Intern Med. 2009;150(11):776–783.
   PubMed Web of Science ®Google Scholar
• Williams B. The hypertension in diabetes study (HDS): a catalyst for change. Diabet Med. 2008;25(Suppl. 2):13–19.
   PubMed Web of Science ®Google Scholar
• Lastra G, Syed S, Kurukulasuriya LR, et al. Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am. 2014;43(1):103–122.
   PubMed Web of Science ®Google Scholar
• DeMarco VG, Habibi J, Jia G, et al. Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice. Hypertension. 2015;66(1):99–107.
   PubMed Web of Science ®Google Scholar
• Frontoni S, Solini A, Fioretto P, et al. The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: a neutral viewoint. Nutr Metab Cardiovas Dis. 2014;24:577–584.
   PubMed Web of Science ®Google Scholar
• Sowers JR. Recent advances in hypertension. J Am Heart Assoc. 2013;61:943–947.
   Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311(5):507–520.
   PubMed Web of Science ®Google Scholar
• The ACCORD study group. Effects of intensive blood pressure control in patients with type 2 diabetes. N Eng J Med. 2010;362:1575–1585.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al., for the INVEST Investigators. A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–2816.
   PubMed Web of Science ®Google Scholar
• The ONTARGET Investigators. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Eng J Med. 2008;358:1547–1559.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(4):413–437.
   Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for management of arterial hypertension. Eur Heart J. 2013;34:2159–2219.
   PubMed Web of Science ®Google Scholar
• Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2014;30(5):485–501.
   PubMed Web of Science ®Google Scholar
• Blumenthal JA, Babyak MA, Hinderliter A, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170(2):126–135.
   PubMed Web of Science ®Google Scholar
• Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–1383.
   PubMed Web of Science ®Google Scholar
• The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–154.
   PubMed Web of Science ®Google Scholar
• Sussman JB, Kent DM, Nelson JP, et al. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of diabetes prevention program. BMJ. 2015;350:h454.
   PubMed Web of Science ®Google Scholar
• Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48:592–598.
   PubMed Web of Science ®Google Scholar
• Bergenstal R, Kim T, Trautmann M, et al. Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes (abstract no. 1239). Circulation. 2008;118:S1086.
   Web of Science ®Google Scholar
• Kurukulasuriya LR, Sowers JR. Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol. 2010;9:45.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al., for the TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Aroor AR, Sowers JR, Jia G, et al. Pleiotropic effecs of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol. 2014;307:H477–H492.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes: UKPDS 34. Lancet. 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• Vijakama P, Thakkinstian A, Lertrattananon D, et al. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55:566–578.
   PubMed Web of Science ®Google Scholar
• Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. Bmj. 2013;347:f6008.
   PubMed Web of Science ®Google Scholar
• Grossman E, Messerli FH. Management of blood pressure in patients with diabetes. Am J Hypertens. 2011;24(8):863–875.
   PubMed Web of Science ®Google Scholar
• Jeffers BW, Bhambri R, Robbins J. Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis. Vasc Health Risk Manag. 2014;10:651–659.
   PubMedGoogle Scholar
• Reboldi G, Gentile G, Angeli F, et al. Optimal therapy in hypertensive subjects with diabetes mellitus. Curr Atheroscler Rep. 2011;13:176–185.
   PubMed Web of Science ®Google Scholar
• Williams B, MacDonald TM, Morant S, et al., for The British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015. DOI:10.1016/S0140-6736(15)00257-3.
   Web of Science ®Google Scholar
• Sowers JR, Lastra G, Rocha R, et al. Initial combination therapy compared with monotherapy in diabetic hypertensive patients. J Clin Hypertens (Greenwich). 2008;10:668–676.
   PubMed Web of Science ®Google Scholar
• Kanda T, Wakino S, Hayashi K, et al. Cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus: proceeding with caution at a dangerous intersection. J Am Soc Nephrol. 2008;19:4–7.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• The SPRINT Research group. A randomized trial of intensive vs standard blood pressure control. NEJM. 2015;373:2103–2116.
   PubMed Web of Science ®Google Scholar
• Perez-Pozo SE, Schold J, Nakagawa T, et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond). 2010;34:454–461.
   PubMed Web of Science ®Google Scholar
• Jia G, Habibi J, Bostick BP, et al. Uric acid promotes left ventricular diastolic dysfunction in mice fed a western diet. Hypertension. 2015;65(3):531–539.
   PubMed Web of Science ®Google Scholar
• DeMarco VG, Sowers JR. Ghrelin: a new incretin enhancer therapy? Diabetes. 2015;64:1500–1502.
   PubMed Web of Science ®Google Scholar